ClinicalTrials.gg
Not yet recruitingNCT07462182Updated Mar 10, 2026

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction

An interventional study of Enoxaparin and Standard Management in Intrauterine Growth Restriction, sponsored by Muhammad Aamir Latif. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.

Read the detailed description

The use of enoxaparin is not yet a standard practice in pregnancies with IUGR and oligohydramnios without overt maternal thrombophilia. Given the notable incidence of IUGR and oligohydramnios and the limited therapeutic options currently available, exploring the potential benefits of enoxaparin therapy against standard management is both clinically and socially relevant. By investigating whether enoxaparin can improve fetal outcomes in this high-risk group, the findings of this study would generate evidence that could inform future management protocols, reduce preventable perinatal morbidity and mortality, and ultimately improve neonatal survival and health in Pakistan.

02

Conditions studied

  • Intrauterine Growth Restriction
03

In context

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

This study's planned enrollment of 108 is below the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.

Browse Fetal Growth Retardation studies →

Lead sponsor

Muhammad Aamir Latif is the lead sponsor of 59 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-40 years
  • Singleton pregnancy
  • Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)
  • Diagnosed with both IUGR and oligohydramnios
  • Willing to provide informed written consent

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Major fetal congenital anomalies
  • Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)
  • Known coagulation disorders or to enoxaparin
  • Women already on anticoagulation therapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Enoxaparin Group

    Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery.

    Drug: Enoxaparin · Other: Standard Management

  • Experimental
    Standard Management Group

    Patients will continue with standard management alone.

    Other: Standard Management

Interventions

  • Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery

  • OtherStandard Management

    Patients will continue with standard management alone.

06

What researchers measure

Primary outcomes

  1. Live birth

    The frequency of live birth will be noted. Delivery of a baby with signs of life at birth, irrespective of gestational age will be considered as live birth.

    Time frame: 12 weeks

  2. Low Birth weight

    Frequency of low birth weight will be noted. Neonatal birth weight \<2.5 kg will be documented as low birth weight.

    Time frame: 12 weeks

Secondary outcomes

  1. Neonatal Intensive Care Unit Admission

    The frequency of admission to the neonatal intensive care unit will be noted.

    Time frame: 7 days

  2. Perinatal Mortality

    Perinatal mortality will be labeled "yes" if there is a stillbirth or neonatal death within the first 7 days of life.

    Time frame: 7 days

07

Study locations

1 site
  • Combined Military Hospital
    Quetta, Balochistan 80000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2026, 5 months later.

Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 5 months is below that.

Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462182
Lead sponsor
Muhammad Aamir Latif
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Sponsor-investigator
First posted
Mar 10, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Maimoona Hafeez
Contact
maimoonahafeez777@gmail.com
+923135495729
Sidra Iqbal, FCPS
Contact
drsidraiqbal4@gmail.com
+923336391038
Maimoona Hafeez
principal investigator · Combined Military Hospital Quetta
Sidra Iqbal, FCPS
study director · Combined Military Hospital Quetta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion